Intellia Therapeutics Announces Promising Phase 3 Trial Results for Lonvo-z, Plans for 2027 U.S. Launch

Reuters

06-16

Intellia <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Promising Phase 3 Trial Results for Lonvo-z, Plans for 2027 U.S. Launch

CAMBRIDGE, Mass. June 15, 2025 (GLOBE NEWSWIRE) - Intellia Therapeutics, Inc. (NASDAQ:NTLA), a clinical-stage gene editing company, has announced three-year follow-up data from the Phase 1 portion of its ongoing Phase 1/2 study in patients with hereditary angioedema $(HAE)$ using a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). The results were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, United Kingdom. The Phase 3 HAELO trial, a global, randomized, double-blind, placebo-controlled study, has completed screening ahead of schedule, with over half of the participants screened in the United States. Intellia plans to report the outcomes of the Phase 3 study in the first half of 2026 and aims to submit a biologics license application $(BLA.AU)$ in 2026 to support a U.S. launch in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intellia Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-141087), on June 16, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2543867970"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2543867970\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2543867970?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-16 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2543867970","market":"fut","top_or_hot":-1,"title":"Intellia Therapeutics Announces Promising Phase 3 Trial Results for Lonvo-z, Plans for 2027 U.S. Launch","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Intellia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Promising Phase 3 Trial Results for Lonvo-z, Plans for 2027 U.S. Launch\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CAMBRIDGE, Mass. June 15, 2025 (GLOBE NEWSWIRE) - Intellia Therapeutics, Inc. (NASDAQ:NTLA), a clinical-stage gene editing company, has announced three-year follow-up data from the Phase 1 portion of its ongoing Phase 1/2 study in patients with hereditary angioedema <a href=\"https://laohu8.com/S/HAE\">$(HAE)$</a> using a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). The results were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, United Kingdom. The Phase 3 HAELO trial, a global, randomized, double-blind, placebo-controlled study, has completed screening ahead of schedule, with over half of the participants screened in the United States. Intellia plans to report the outcomes of the Phase 3 study in the first half of 2026 and aims to submit a biologics license application <a href=\"https://laohu8.com/S/BLA.AU\">$(BLA.AU)$</a> in 2026 to support a U.S. launch in 2027.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/NTLA\">Intellia Therapeutics Inc</a>. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-141087), on June 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intellia Therapeutics Announces Promising Phase 3 Trial Results for Lonvo-z, Plans for 2027 U.S. Launch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntellia Therapeutics Announces Promising Phase 3 Trial Results for Lonvo-z, Plans for 2027 U.S. Launch\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-16 19:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Intellia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Promising Phase 3 Trial Results for Lonvo-z, Plans for 2027 U.S. Launch\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CAMBRIDGE, Mass. June 15, 2025 (GLOBE NEWSWIRE) - Intellia Therapeutics, Inc. (NASDAQ:NTLA), a clinical-stage gene editing company, has announced three-year follow-up data from the Phase 1 portion of its ongoing Phase 1/2 study in patients with hereditary angioedema <a href=\"https://laohu8.com/S/HAE\">$(HAE)$</a> using a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). The results were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, United Kingdom. The Phase 3 HAELO trial, a global, randomized, double-blind, placebo-controlled study, has completed screening ahead of schedule, with over half of the participants screened in the United States. Intellia plans to report the outcomes of the Phase 3 study in the first half of 2026 and aims to submit a biologics license application <a href=\"https://laohu8.com/S/BLA.AU\">$(BLA.AU)$</a> in 2026 to support a U.S. launch in 2027.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/NTLA\">Intellia Therapeutics Inc</a>. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-141087), on June 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4556","symbol_name":"基因编辑","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250616:nNDL8Fnvr1:1","article_id":"2543867970","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2543867970","pubTimestamp":1750071692,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CAMBRIDGE, Mass. June 15, 2025  - Intellia Therapeutics, Inc. , a clinical-stage gene editing company, has announced three-year follow-up data from the Phase 1 portion of its ongoing Phase 1/2 study in patients with hereditary angioedema  using a single dose of lonvoguran ziclumeran . The results were presented at the European Academy of Allergy and Clinical Immunology  Congress 2025 in Glasgow, United Kingdom. The Phase 3 HAELO trial, a global, randomized, double-blind, placebo-controlled study, has completed screening ahead of schedule, with over half of the participants screened in the United States. Intellia plans to report the outcomes of the Phase 3 study in the first half of 2026 and aims to submit a biologics license application  in 2026 to support a U.S. launch in 2027.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4556":"基因编辑","BK4588":"碎股","BK4585":"ETF&股票定投概念","NTLA":"Intellia Therapeutics Inc","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4139":"生物科技","BK4535":"淡马锡持仓","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD"},"translate_title":"Intellia Therapeutics宣布Lonvo-z有希望的3期试验结果，计划于2027年在美国上市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTLA":0.9},"content_text":"Intellia Therapeutics Announces Promising Phase 3 Trial Results for Lonvo-z, Plans for 2027 U.S. Launch\n    \n\n        CAMBRIDGE, Mass. June 15, 2025 (GLOBE NEWSWIRE) - Intellia Therapeutics, Inc. (NASDAQ:NTLA), a clinical-stage gene editing company, has announced three-year follow-up data from the Phase 1 portion of its ongoing Phase 1/2 study in patients with hereditary angioedema $(HAE)$ using a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). The results were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, United Kingdom. The Phase 3 HAELO trial, a global, randomized, double-blind, placebo-controlled study, has completed screening ahead of schedule, with over half of the participants screened in the United States. Intellia plans to report the outcomes of the Phase 3 study in the first half of 2026 and aims to submit a biologics license application $(BLA.AU)$ in 2026 to support a U.S. launch in 2027.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intellia Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-141087), on June 16, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease,dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}